• Thu, December 12, 2024

Lonza to exit capsules and health ingredients business, focus on contract development

Swiss contract drug manufacturer Lonza announced on Thursday it plans to exit the capsules and health ingredients business. The Basel-based group will focus on its contract development and manufacturing organization (CDMO) business,
Lonza, a Swiss contract drug manufacturer, has announced its decision to exit its capsules and health ingredients business in order to concentrate on its core activities of contract development and manufacturing for the pharmaceutical and biotech industries. This strategic shift aims to streamline operations and enhance focus on high-growth areas. Lonza plans to explore strategic options for its capsules and nutritional ingredients units, which could involve selling these segments. The move is part of Lonza's broader strategy to optimize its portfolio and drive long-term growth by investing in areas with significant potential for innovation and expansion.

Read the Full MSN Article at:
https://www.msn.com/en-us/money/general/lonza-to-exit-capsules-and-health-ingredients-business-focus-on-contract-development/ar-AA1vIwok

Like: 👍